MCID: ASP006
MIFTS: 73

Aspergillosis

Categories: Genetic diseases, Infectious diseases, Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Aspergillosis

MalaCards integrated aliases for Aspergillosis:

Name: Aspergillosis 57 11 19 58 75 53 41 2 43 14 16 71 31 33
Aspergillosis, Susceptibility to 57 28 5 38
Intracavitary Aspergillus Fungus Ball 33
Infection by Aspergillus Fumigatus 33
Aspergillus Fumigatus Infection 33
Infection Due to Aspergillus 11
Aspergillus Flavus Infection 33
Aspergillus Infection 33
Simple Aspergilloma 33
Aspergillus Terreus 33
Aspergillus Nodule 33
Aspergilloma 33
Aspergillus 33

Characteristics:


Age Of Onset:

All ages 58

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Aspergillosis

GARD: 19 Aspergillosis is an infection, growth, or allergic response caused by the Aspergillus fungus. There are several different kinds of Aspergillosis. One kind is allergic bronchopulmonary Aspergillosis (also called ABPA), a condition where the fungus causes allergic respiratory symptoms similar to asthma, such as wheezing and coughing, but does not actually invade and destroy tissue. Another kind of Aspergillosis is invasive Aspergillosis. This infection usually affects people with weakened immune systems due to cancer, AIDS, leukemia, organ transplantation, chemotherapy, or other conditions or events that reduce the number of normal white blood cells. In this condition, the fungus invades and damages tissues in the body. Invasive Aspergillosis most commonly affects the lungs, but can also cause infection in many other organs and can spread throughout the body (commonly affecting the kidneys and brain). Aspergilloma, a growth (fungus ball) that develops in an area of previous lung disease such as tuberculosis or lung abscess, is a third kind of Aspergillosis. This type of Aspergillosis is composed of a tangled mass of fungus fibers, blood clots, and white blood cells. The fungus ball gradually enlarges, destroying lung tissue in the process, but usually does not spread to other areas.

MalaCards based summary: Aspergillosis, also known as aspergillosis, susceptibility to, is related to allergic bronchopulmonary aspergillosis and invasive aspergillosis, and has symptoms including fever and pruritus. An important gene associated with Aspergillosis is CLEC7A (C-Type Lectin Domain Containing 7A), and among its related pathways/superpathways are ERK Signaling and Innate Immune System. The drugs Cathine and Guaifenesin have been mentioned in the context of this disorder. Affiliated tissues include lung, kidney and skin, and related phenotypes are cough and positive blood 1,3 beta glucan test

MedlinePlus: 41 Aspergillosis is a disease caused by a fungus (or mold) called Aspergillus. The fungus is very common in both indoors and outdoors. Most people breathe in the spores of the fungus every day without being affected. But some people get the disease. It usually occurs in people with lung diseases or weakened immune systems. There are different kinds of aspergillosis. One kind is allergic bronchopulmonary aspergillosis (also called ABPA). Symptoms of ABPA include wheezing and coughing. ABPA can affect healthy people but it is most common in people with asthma or cystic fibrosis. Another kind is invasive aspergillosis, which damages tissues in the body. It usually affects the lungs. Sometimes it can also cause infection in other organs and spread throughout the body. It affects people who have immune system problems, such as people who have had a transplant, are taking high doses of steroids, or getting chemotherapy for some cancers. Your doctor might do a variety of tests to make the diagnosis, including a chest x-ray, CT scan of the lungs, and an examination of tissues for signs of the fungus. Treatment is with antifungal drugs. If you have ABPA, you may also take steroids. Centers for Disease Control and Prevention

OMIM®: 57 Aspergillus species are ubiquitous in nature and cause a wide spectrum of diseases, including saprophytic colonization of existing cavities (aspergilloma), allergic asthma, hypersensitivity pneumonitis, allergic bronchopulmonary aspergillosis, and disseminated disease associated with high mortality rates in patients with hematologic malignancies and recipients of solid organs and stem cell transplantations. Immunocompetent and nonatopic individuals are relatively resistant to infection, and disease occurs in the setting of host damage. Association of persistent inflammation with intractable infection is common in nonneutropenic patients after hematopoietic stem cell transplantation, as well as in allergic fungal diseases. The pathophysiology underlying Aspergillus infection highlights the bipolar nature of the inflammatory process in infection, in which early inflammation prevents or limits infection, but an uncontrolled response may oppose disease eradication (summary by Cunha et al., 2010). For information on familial occurrence of allergic bronchopulmonary aspergillosis, see 103920. (614079) (Updated 08-Dec-2022)

Orphanet: 58 A rare infectious disease caused by inhalation of the opportunistic fungus aspergillus that can lead to the following manifestations: allergic bronchopulmonary aspergillosis (ABPA), aspergilloma, chronic necrotizing pulmonary aspergillosis (CNPA), and invasive aspergillosis (IA). Aspergilloma occurs in patients with cavitary lung disease and results in a fungal mass with variable clinical presentations from asymptomatic to life-threatening (massive hemoptysis). CNPA manifests as subacute pneumonia in patients with underlying disease. IA is disseminated aspergillosis that eventually invades other organs. Cutaneous aspergillosis is usually the dermatological manifestation of IA that manifests as erythematous-to-violaceous plaques or papules, often characterized by a central necrotic ulcer or eschar.

CDC: 2 Aspergillosis is an infection caused by Aspergillus, a common mold (a type of fungus) that lives indoors and outdoors. Most people breathe in Aspergillus spores every day without getting sick. However, people with weakened immune systems or lung diseases are at a higher risk of developing health problems due to Aspergillus. The types of health problems caused by Aspergillus include allergic reactions, lung infections, and infections in other organs.

Disease Ontology: 11 An opportunistic mycosis that involves a spectrum of diseases of humans and animals caused by members of the genus Aspergillus infecting lungs, brain, kidney, heart, bone, eyes, sinuses, skin and gastrointestinal tract. It is a serious illnesses in people with a weakened immune system.

Wikipedia: 75 Aspergillosis is a fungal infection of usually the lungs, caused by the genus Aspergillus, a common... more...

Related Diseases for Aspergillosis

Diseases in the Aspergillosis family:

Invasive Aspergillosis

Diseases related to Aspergillosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1826)
# Related Disease Score Top Affiliating Genes
1 allergic bronchopulmonary aspergillosis 32.9 SFTPD MBL2 IL5 IL4 IFNG CLEC7A
2 invasive aspergillosis 32.5 TNF TLR9 TLR4 TLR2 PTX3 IL6
3 bronchiectasis 31.6 TNF TLR2 MBL2 IL6 IL1B IFNG
4 hypereosinophilic syndrome 31.6 IL5 IL4 IL10 IFNG
5 graft-versus-host disease 31.5 TNF IL10 IFNG CSF3
6 chronic granulomatous disease 31.4 TNF IL1B IFNG CSF3 CLEC7A
7 neutropenia 31.3 TNF TLR4 MBL2 IL6 IL4 IL1B
8 mucormycosis 31.2 TNF IL6 IL10 IFNG CSF3 CLEC7A
9 acquired immunodeficiency syndrome 31.2 TNF IL6 IL1B IL10 IFNG CCL3
10 pulmonary fibrosis 31.0 SFTPD IL1B ELANE CCL3
11 leukemia, acute myeloid 31.0 TNF IL6 IL4 IL1B IL10 IFNG
12 acute graft versus host disease 31.0 TNF IL10 IFNG CSF3
13 candidiasis 31.0 TNF TLR4 TLR2 MBL2 IL6 IL5
14 pulmonary tuberculosis 31.0 TNF TLR4 TLR2 MBL2 IL6 IL4
15 endophthalmitis 31.0 TNF TLR2 IL6 IL1B
16 fungal infectious disease 31.0 TNF TLR9 TLR4 TLR2 IL6 IL5
17 endocarditis 31.0 TNF TLR2 IL6 IL10 IFNG
18 ige responsiveness, atopic 31.0 IL5 IL4 IL10 IFNG
19 rhinitis 30.9 TNF TLR4 IL6 IL5 IL4 IL1B
20 lung abscess 30.9 TNF IL6 IL1B IFNG
21 adult respiratory distress syndrome 30.9 TNF SFTPD IL6 IL1B IL10 ELANE
22 bronchitis 30.9 TNF TLR4 TLR2 IL6 IL5 IL4
23 corneal ulcer 30.9 TNF IL6 IL1B CLEC7A
24 churg-strauss syndrome 30.9 TNF IL5 IL1B IL10
25 toxic shock syndrome 30.8 TNF TLR4 TLR2 IL6 IL4 IL1B
26 anthracosis 30.8 TNF IL6 IL1B
27 macs syndrome 30.8 TNF IL10 IFNG
28 purpura 30.8 TNF IL6 IL4 IL1B IL10 IFNG
29 osteomyelitis 30.8 TNF TLR4 TLR2 IL6 IL4 IL1B
30 pneumoconiosis 30.8 TNF MBL2 IL6 IL1B IL10
31 pulmonary disease, chronic obstructive 30.7 TNF TLR2 SFTPD IL6 IL1B ELANE
32 bronchopneumonia 30.7 TNF IL6 IL1B IL10 ELANE CCL3
33 cystic fibrosis 30.7 TNF TLR9 TLR4 TLR2 SFTPD PTX3
34 vasculitis 30.7 TNF PTX3 MBL2 IL6 IL1B IL10
35 allergic asthma 30.7 TLR4 TLR2 IL5 IL4 IL10 IFNG
36 cryptococcosis 30.7 TNF PTX3 MBL2 IL4 IL10 IFNG
37 allergic rhinitis 30.7 IL5 IL4 IL10 IFNG
38 pancytopenia 30.7 IL6 IFNG CSF3 CSF1
39 covid-19 30.7 TNF TLR4 IL6 IL4 IL1B IL10
40 lymphopenia 30.7 IL6 IL4 IL10 IFNG CCR6
41 chronic eosinophilic pneumonia 30.7 IL6 IL5 CSF3 CCL3
42 severe acute respiratory syndrome 30.7 TNF TLR4 MBL2 IL6 IL4 IL1B
43 alveolar echinococcosis 30.7 IL5 IL4 IL10
44 pericarditis 30.6 TNF IL6 IL1B IFNG
45 pulmonary eosinophilia 30.6 SFTPD IL5 IL4 CCL3
46 miliary tuberculosis 30.6 TNF IL4 IL10 IFNG
47 myelodysplastic syndrome 30.6 TNF IL6 IL1B CSF3 CSF1 CCR6
48 legionnaire disease 30.6 TNF TLR2 IL6 IL1B
49 back pain 30.6 IL6 IL1B IL10
50 human cytomegalovirus infection 30.6 TNF IL6 IL10 CCR6

Comorbidity relations with Aspergillosis via Phenotypic Disease Network (PDN):


Bronchiectasis Bronchitis
Deficiency Anemia Heart Disease
Postinflammatory Pulmonary Fibrosis Respiratory Failure

Graphical network of the top 20 diseases related to Aspergillosis:



Diseases related to Aspergillosis

Symptoms & Phenotypes for Aspergillosis

Human phenotypes related to Aspergillosis:

58 30 (show top 50) (show all 63)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 cough 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0012735
2 positive blood 1,3 beta glucan test 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0020153
3 fever 58 30 Frequent (33%) Frequent (79-30%)
HP:0001945
4 immunodeficiency 58 30 Frequent (33%) Frequent (79-30%)
HP:0002721
5 hemoptysis 58 30 Frequent (33%) Frequent (79-30%)
HP:0002105
6 chest pain 58 30 Frequent (33%) Frequent (79-30%)
HP:0100749
7 neutropenia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001875
8 eosinophilia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001880
9 chronic lung disease 58 30 Frequent (33%) Frequent (79-30%)
HP:0006528
10 abnormality on pulmonary function testing 58 30 Frequent (33%) Frequent (79-30%)
HP:0030878
11 parenchymal consolidation 58 30 Frequent (33%) Frequent (79-30%)
HP:0032177
12 ground-glass opacification 30 Frequent (33%) HP:0025179
13 visual impairment 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000505
14 sinusitis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000246
15 hepatitis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012115
16 asthma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002099
17 dyspnea 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002094
18 abnormality of the kidney 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000077
19 keratitis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000491
20 headache 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002315
21 pneumonia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002090
22 hematological neoplasm 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0004377
23 pulmonary fibrosis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002206
24 pleuritis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002102
25 diffuse reticular or finely nodular infiltrations 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002207
26 dacryocystitis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000620
27 localized skin lesion 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0011355
28 ocular pain 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0200026
29 abnormal esophagus morphology 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002031
30 rhinorrhea 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0031417
31 hypersensitivity pneumonitis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0006516
32 invasive pulmonary aspergillosis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0020103
33 increased circulating ige level 30 Occasional (7.5%) HP:0003212
34 nasal congestion 30 Occasional (7.5%) HP:0001742
35 chronic pulmonary obstruction 30 Occasional (7.5%) HP:0006510
36 seizure 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001250
37 bronchiectasis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002110
38 stroke 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001297
39 abnormality of the vertebral column 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000925
40 meningitis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001287
41 osteomyelitis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002754
42 intracranial hemorrhage 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002170
43 pleural effusion 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002202
44 functional motor deficit 58 30 Very rare (1%) Very rare (<4-1%)
HP:0004302
45 periorbital fullness 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000629
46 vitritis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0011531
47 abnormality of the skull base 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002693
48 abnormal rib morphology 30 Very rare (1%) HP:0000772
49 abnormal long bone morphology 30 Very rare (1%) HP:0011314
50 infectious encephalitis 30 Very rare (1%) HP:0002383

Clinical features from OMIM®:

614079 (Updated 08-Dec-2022)

UMLS symptoms related to Aspergillosis:


fever; pruritus

GenomeRNAi Phenotypes related to Aspergillosis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.19 CCL3 CCR6 CLEC1A CLEC7A CSF1 CSF3
2 no effect GR00402-S-2 10.19 CCL3 CCR6 CLEC1A CLEC7A CSF1 CSF3
3 Reduced mammosphere formation GR00396-S 9.5 CCL3 CCR6 CLEC7A CSF1 CSF3 IL5

MGI Mouse Phenotypes related to Aspergillosis:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 CCL3 CCR6 CLEC7A CSF1 ELANE IFNG
2 immune system MP:0005387 10.37 CCL3 CCR6 CLEC1A CLEC7A CSF1 CSF3
3 cellular MP:0005384 10.18 CCL3 CLEC1A CSF1 IFNG IL10 IL4
4 digestive/alimentary MP:0005381 10.17 CCL3 CLEC7A IFNG IL10 IL4 IL5
5 neoplasm MP:0002006 10.16 ELANE IFNG IL10 IL1B IL5 IL6
6 hematopoietic system MP:0005397 10.16 CCL3 CCR6 CLEC1A CLEC7A CSF1 CSF3
7 liver/biliary system MP:0005370 10.13 CSF1 IFNG IL10 IL4 IL5 IL6
8 renal/urinary system MP:0005367 10.1 CSF3 IFNG IL4 IL6 MBL2 TLR2
9 respiratory system MP:0005388 10.1 CLEC7A CSF1 IFNG IL10 IL4 IL5
10 skeleton MP:0005390 9.96 CSF1 IFNG IL10 IL1B IL4 IL6
11 mortality/aging MP:0010768 9.8 CCL3 CLEC7A CSF1 ELANE IFNG IL10
12 integument MP:0010771 9.36 CSF1 CSF3 ELANE IFNG IL10 IL1B

Drugs & Therapeutics for Aspergillosis

Drugs for Aspergillosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
2
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
3
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
4
Isavuconazole Approved, Investigational Phase 4 241479-67-4 21937662
5
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
6
Omalizumab Approved, Investigational Phase 4 242138-07-4
7
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
8 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
9 Antitussive Agents Phase 4
10 Immunoglobulins, Intravenous Phase 4
11 Immunoglobulin E Phase 4
12 Anti-Allergic Agents Phase 4
13
Hydroxyitraconazole Phase 4 108222
14
Budesonide Approved Phase 2, Phase 3 51333-22-3 5281004 40000 63006
15
Deoxycholic acid Approved Phase 2, Phase 3 83-44-3 222528
16
Fluticasone Approved, Experimental Phase 2, Phase 3 90566-53-3 4659387 5311101
17
Iron Approved Phase 3 7439-89-6 29936
18
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2
19
Midazolam Approved, Illicit Phase 2, Phase 3 59467-70-8 4192
20
Ibrexafungerp Approved, Investigational Phase 3 1207753-03-4 75163792
21
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 2826718
22
Deflazacort Approved, Investigational Phase 2, Phase 3 14484-47-0 26709 189821
23
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
24
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
25
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
26
Sulfamethoxazole Approved Phase 3 723-46-6 5329
27
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 67-97-0, 1406-16-2 5280795 10883523
28
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
29
Rezafungin Investigational Phase 3 1396640-59-7
30 Hemostatics Phase 2, Phase 3
31 Amphotericin B, deoxycholate drug combination Phase 2, Phase 3
32 Formoterol Fumarate Phase 2, Phase 3
33 Xhance Phase 2, Phase 3
34 Vitamins Phase 2, Phase 3
35 Trace Elements Phase 2, Phase 3
36 Calciferol Phase 2, Phase 3
37 Micronutrients Phase 2, Phase 3
38
Epoetin Alfa Phase 3
39 Chrysarobin Phase 3
40 Amebicides Phase 3
41 Echinocandins Phase 3
42 Folic Acid Antagonists Phase 3
43 Folate Phase 3
44 Vitamin B9 Phase 3
45 Vitamin B Complex Phase 3
46 Antimalarials Phase 3
47 Trimethoprim, Sulfamethoxazole Drug Combination Phase 3
48
Amphotericin B Approved, Investigational Phase 2 1397-89-3 5280965
49
Nitric Oxide Approved Phase 2 10102-43-9 145068
50
Olorofim Investigational Phase 2 1928707-56-5

Interventional clinical trials:

(show top 50) (show all 211)
# Name Status NCT ID Phase Drugs
1 Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation Unknown status NCT00986713 Phase 4 Amphotericin B
2 Efficacy and Safety of Voriconazole for Treatment of Invasive Pulmonary Aspergillosis Secondary to COPD: a Multi-center Prospective,Open Cohort Study (VIA-COPD) Unknown status NCT02234739 Phase 4 Voriconazole
3 Prospective, Open-label Study of the Efficacy and Safety of Caspofungin for the Treatment of Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
4 A RANDOMIZED CONTROLLED STUDY OF ITRACONAZOLE IN CHRONIC CAVITARY PULMONARY ASPERGILLOSIS Completed NCT01259336 Phase 4 Itraconazole;treatment in cavitary pulmonary aspergillosis
5 A Phase iv, Interventional, Non-blinded, Randomized Controlled Multicenter Study of Posaconazole Prophylaxis for the Prevention of Influenza-associated Aspergillosis (IAA) in Critically Ill Patients Completed NCT03378479 Phase 4 SOC +Posaconazole 18 MG/ML (milligram/milliliter)
6 AmBisome® in Combination With Caspofungin Versus AmBisome® High Dose Regimen for the Treatment of Invasive Aspergillosis in Immunocompromized Patients: Randomized Pilot Study. Completed NCT00334412 Phase 4 Ambisome;caspofungin
7 An Open Label, Non-comparative, Multicenter Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infection Completed NCT00647907 Phase 4 Voriconazole
8 A Randomized Controlled Trial of the Effect of Cytochrome P450 2C19 Genotype-Specific Dosing Plus TDM vs. TDM Alone on Reaching Therapeutic Voriconazole Blood Levels Completed NCT03731169 Phase 4 Standard of Care
9 A Phase 4, Open Label Study To Assess The Bronchopulmonary Pharmacokinetics Of Anidulafungin And Voriconazole Following Intravenous Administration In Healthy Subjects Completed NCT00940017 Phase 4 anidulafungin and voriconazole
10 Treatment of Aspergillus Fumigatus in Patients With Cystic Fibrosis: A Randomized, Double-blind, Placebo-Controlled Trial Completed NCT00528190 Phase 4 Itraconazole
11 Randomized and Multicenter Clinical Trial to Evaluate the Effectiveness and Efficiency of a Voriconazole Preemptive Genotyping Strategy in Patients With Risk of Aspergillosis Recruiting NCT04238884 Phase 4 Voriconazole preemptive genotyping strategy;Voriconazole clinical practice
12 Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection Recruiting NCT03717623 Phase 4 Posaconazole pharmacokinetics
13 A SINGLE ARM, PROSPECTIVE, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF ISAVUCONAZOLE FOR PRIMARY TREATMENT OF CHINESE PATIENTS WITH INVASIVE FUNGAL DISEASE (IFD) CAUSED BY ASPERGILLUS SPECIES OR OTHER FILAMENTOUS FUNGI Not yet recruiting NCT05630976 Phase 4 Isavuconazole
14 An Exploratory, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy of Multiple Doses of Omalizumab in Cystic Fibrosis Complicated by Allergic Bronchopulmonary Aspergillosis (ABPA) Terminated NCT00787917 Phase 4 Omalizumab;Placebo;Itraconazole
15 A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Aspergillosis (CFDA Commitment) Terminated NCT02646774 Phase 4 Micafungin
16 Phase IV Open-Label Pilot Study to Evaluate the Combination of Voriconazole and Anidulafungin for the Treatment of Subjects With Proven or Probable Invasive Aspergillosis Who Are Intolerant of Polyene Treatment Terminated NCT00620074 Phase 4 voriconazole;anidulafungin
17 A Multi-center, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Terminated NCT02646800 Phase 4 Micafungin
18 Phase IV, Single-Center, Open-Label Study Evaluating the Effects of an Anti-IL5 Receptor Alpha (Benralizumab) Monoclonal Antibody in the Treatment of Severe Asthma in Patients With Allergic Bronchopulmonary Aspergillosis Withdrawn NCT04108962 Phase 4 Fasenra, 30 Mg/mL Subcutaneous Solution
19 A Double-Blind, Randomized Controlled Trial of Voriconazole (VFEND®) Plus Micafungin (MYCAMINE™) Versus Voriconazole Plus Placebo in the Treatment of Patients With Proven or Probable Invasive Aspergillosis Withdrawn NCT00423163 Phase 4 micafungin;voriconazole
20 Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis. Open Label Phase III Clinical Study Unknown status NCT01125644 Phase 3 SPK-843
21 Efficacy of Intrabronchial Voriconazole Instillation for Inoperable Pulmonary Aspergilloma- a Randomized Controlled Trial Unknown status NCT03799809 Phase 2, Phase 3 Intrabronchial Voriconazole instillation
22 A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis Completed NCT01857479 Phase 2, Phase 3 Inhaled budesonide;Inhaled amphotericin
23 A Randomized Controlled Trial of Voriconazole in Allergic Bronchopulmonary Aspergillosis Completed NCT01621321 Phase 2, Phase 3 Prednisolone;Voriconazole
24 A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma Completed NCT03133299 Phase 2, Phase 3 Glucocorticoids;Vitamin D
25 Randomized Controlled Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis Completed NCT00974766 Phase 2, Phase 3 Glucocorticoids
26 A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis Completed NCT02440009 Phase 2, Phase 3 Itraconazole;Glucocorticoids
27 A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069) Completed NCT01782131 Phase 3 Posaconazole;Voriconazole;Placebo
28 Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis Completed NCT01321827 Phase 2, Phase 3 Glucocorticoids;Itraconazole
29 A Multicentre Randomised Controlled Trial Comparing the Current Standard Diagnostic Strategy for Invasive Aspergillosis to the New Diagnostic Strategy for Invasive Aspergillosis in High-Risk Haematology Patients in Order to Determine Which Strategy Results in the Lower Rates of Use of Empiric Antifungal Therapy Completed NCT00163722 Phase 3
30 A Randomized Controlled Trial to Compare the Clinical Outcomes of Six Months Versus 12 Months of Oral Itraconazole Therapy for Management of Treatment naïve Subjects With Chronic Pulmonary Aspergillosis Completed NCT03920527 Phase 3 Itraconazole 400 mg
31 Voriconazole For Primary Therapy Of Proven, Chronic Bronchopulmonary Aspergillosis, In Minimally Immunocompromised Or, Non-Immunocompromised Hosts Completed NCT00159822 Phase 2, Phase 3 Voriconazole
32 A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Erythropoietin-stimulating Agents Completed NCT02879305 Phase 3 Daprodustat;rhEPO;Placebo;Iron therapy
33 Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi Completed NCT00634049 Phase 3 isavuconazole
34 A Prospective, Randomized Trial Comparing The Efficacy Of Anidulafungin And Voriconazole In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Proven Or Probable Invasive Aspergillosis Completed NCT00531479 Phase 3 voriconazole;anidulafungin
35 Study of the Safety and Efficacy of AmBisome Loading Dose Regimen Vs. a Standard AmBisome Regimen for Initial Treatment of Invasive Aspergillosis and Other Filamentous Fungal Infections in Immunocompromised Patients Completed NCT00158730 Phase 3 AmBisome
36 An Open Label Non-Comparative Study of the Safety and Efficacy of Intravenous Anidulafungin Plus AmBisome® [(Amphotericin B) Liposome for Injection] as a Treatment for Invasive Aspergillosis. Completed NCT00037206 Phase 2, Phase 3 Anidulafungin, VER002
37 An Open Randomised Comparative Multicentre Study of the Efficacy, Safety and Toleration of Voriconazole Versus Amphotericin-B in the Treatment of Acute Invasive Aspergillosis in Immunocompromised Patients Completed NCT00003031 Phase 3 amphotericin B deoxycholate;voriconazole
38 Nebulized Liposomal Amphotericin B (Ambisome) Versus Nebulized Placebo for the Prophylaxis of Invasive Pulmonary Aspergillosis in Haematological Patients With Prolonged Neutropenia. A Randomized Clinical Trial. Completed NCT00263315 Phase 2, Phase 3 nebulised liposomal amphotericin B
39 Using Serum Galactomannan Levels in a Prospective, Randomised, Non-blinded Trial to Guide Early Anti-fungal Therapy in Haematology Patients at Risk of Invasive Aspergillosis. Completed NCT00361517 Phase 3 Amphotericin-B deoxycholate
40 Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis Completed NCT00001646 Phase 3 Voriconazole;Amphotericin B
41 A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi. Completed NCT00412893 Phase 3 Isavuconazole;Voriconazole
42 A Pharmacokinetic Study of JK1211 in Patients With Systemic Fungal Infection (SFI) and Patients With Febrile Neutropenia (FN) Suspected of Fungal Infection. Completed NCT00784368 Phase 3 ITCZ Oral Solution;ITCZ-IV
43 An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections Completed NCT00001810 Phase 3 Voriconazole
44 A Phase III, Randomized, Double-Blind, Comparative Trial of FK463 Versus Fluconazole for Prophylaxis of Fungal Infections in Patients Undergoing a Hematopoetic Stem Cell Transplant Completed NCT00001937 Phase 3 FK463;Fluconazole
45 A Randomized, Comparative, Open-label Study to Assess the Safety and Efficacy of MK-5592 Compared With Voriconazole in Japanese Subjects With Deep-seated Fungal Infection Completed NCT02180165 Phase 3 Posaconazole;Voriconazole
46 A Multicenter, Double-Blind, Comparative Study of MK0991 (Caspofungin) Versus Micafungin in Adult Japanese Patients With Deep-seated Candida or Aspergillus Infections Completed NCT00717860 Phase 3 caspofungin acetate;Comparator: Micafungin sodium
47 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
48 Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI) Recruiting NCT03059992 Phase 3 Ibrexafungerp
49 A Randomized Controlled Trial of Deflazacort vs. Prednisolone in Acute-stage Allergic Bronchopulmonary Aspergillosis Recruiting NCT04227483 Phase 2, Phase 3 Deflazacort;Prednisolone
50 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis Recruiting NCT04442269 Phase 3 dupilumab;Placebo

Search NIH Clinical Center for Aspergillosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Caspofungin
Caspofungin acetate
Flucytosine
Itraconazole
Miconazole
Miconazole Nitrate
MICONAZOLE NITRATE PWDR
voriconazole

Cochrane evidence based reviews: aspergillosis

Genetic Tests for Aspergillosis

Genetic tests related to Aspergillosis:

# Genetic test Affiliating Genes
1 Aspergillosis, Susceptibility to 28 CLEC1A CLEC7A

Anatomical Context for Aspergillosis

Organs/tissues related to Aspergillosis:

MalaCards : Lung, Kidney, Skin, Bone, Brain, Heart, Myeloid

Publications for Aspergillosis

Articles related to Aspergillosis:

(show top 50) (show all 41556)
# Title Authors PMID Year
1
Recognition of DHN-melanin by a C-type lectin receptor is required for immunity to Aspergillus. 62 57 5
29489751 2018
2
Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. 62 57 5
20807886 2010
3
Toll-like receptor 4 polymorphisms and aspergillosis. 53 62 57
19196681 2009
4
Toll-like receptor 4 polymorphisms and aspergillosis. 53 62 57
19202579 2009
5
Toll-like receptor 4 polymorphisms and aspergillosis. 53 62 57
19202580 2009
6
Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. 53 62 57
18946062 2008
7
Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. 53 62 57
18275280 2008
8
Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. 62 57
16247433 2005
9
Phenotypic Variants of Azole-Resistant Aspergillus Fumigatus that Co-exist in Human Respiratory Samples are Genetically Highly Related. 62 41
36098829 2022
10
Role of biomarkers in the diagnosis of invasive aspergillosis in immunocompromised patients. 62 41
36320074 2022
11
Uptake of the Siderophore Triacetylfusarinine C, but Not Fusarinine C, Is Crucial for Virulence of Aspergillus fumigatus. 62 41
36125294 2022
12
Human dectin-1 deficiency and mucocutaneous fungal infections. 5
19864674 2009
13
TLR polymorphisms and the risk of invasive fungal infections. 57
18946070 2008
14
Identification of a human homologue of the dendritic cell-associated C-type lectin-1, dectin-1. 57
11470510 2001
15
Cloning of human DECTIN-1, a novel C-type lectin-like receptor gene expressed on dendritic cells. 57
11491532 2001
16
Susceptibility of mice genetically deficient in SP-A or SP-D gene to invasive pulmonary aspergillosis. 53 62
20413160 2010
17
Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients. 53 62
19827955 2009
18
Identification of Aspergillus species in oral tissue samples of patients with hematologic malignancies by in situ hybridization: a preliminary report. 53 62
18718399 2008
19
Protective role of mannan-binding lectin in a murine model of invasive pulmonary aspergillosis. 53 62
17335555 2007
20
Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. 53 62
17311505 2007
21
Chemokines in allergic aspergillosis--from animal models to human lung diseases. 53 62
17168792 2006
22
[Clinical analysis of chronic pulmonary aspergillosis and discovery of an elastase inhibitor]. 53 62
16940951 2006
23
[A case of idiopathic pulmonary upper lobe fibrosis complicated by invasive pulmonary aspergillosis]. 53 62
12772600 2003
24
[Successful treatment of invasive pulmonary aspergillosis with G-CSF and M-CSF during long-term bone marrow suppression in hypoplastic leukemia]. 53 62
11979751 2002
25
Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis. 53 62
11474427 2001
26
Recombinant human macrophage colony-stimulating factor augments pulmonary host defences against Aspergillus fumigatus. 53 62
11500084 2001
27
A 1.1-kb duplication in the p67-phox gene causes chronic granulomatous disease. 53 62
11499676 2001
28
Protective role of lung surfactant protein D in a murine model of invasive pulmonary aspergillosis. 53 62
11254642 2001
29
Macrophage inflammatory protein-1 alpha is a critical mediator of host defense against invasive pulmonary aspergillosis in neutropenic hosts. 53 62
10878372 2000
30
[Aspergillosis: Mechanisms of pathogenicity implicated and approach to laboratory diagnosis.]. 53 62
17655396 1998
31
Lung surfactant proteins A and D can inhibit specific IgE binding to the allergens of Aspergillus fumigatus and block allergen-induced histamine release from human basophils. 53 62
9367408 1997
32
Polymerase chain reaction amplification of Asp f I and alkaline protease genes from fungus balls: clinical application in pulmonary aspergillosis. 53 62
9058095 1997
33
[Invasive pulmonary aspergillosis in a patient with acute leukemia--the role of neutrophil elastase in in cavity formation]. 53 62
8691669 1996
34
[Protective effect of human macrophage colony-stimulating factor on fungal infection (2). In vitro effect of human macrophage colony-stimulating factor on systemic aspergillosis and in vitro effect on the activities of macrophage]. 53 62
7602192 1995
35
Western blot detection of IgG anti-Aspergillus fumigatus elastase in sera of patients with aspergillosis. 53 62
7965494 1994
36
Lack of vessel wall elastolysis in human invasive pulmonary aspergillosis. 53 62
1452348 1992
37
Control of proven pulmonary and suspected CNS aspergillus infection with itraconazole in a patient with chronic granulomatous disease. 53 62
1655460 1991
38
[Aspergillus mastoiditis in infected granulomatosis--a case report]. 53 62
2165779 1990
39
Fermentative features of Bacillus velezensis and Leuconostoc mesenteroides in doenjang-meju, a Korean traditional fermented soybean brick. 62
36462832 2023
40
Detection of wheat toxigenic Aspergillus flavus based on nano-composite colorimetric sensing technology. 62
36371840 2023
41
Citral and cinnamaldehyde - Pickering emulsion stabilized by zein coupled with chitosan against Aspergillus. spp and their application in food storage. 62
36174341 2023
42
Reduction of Aspergillus flavus and aflatoxin on almond kernels using gaseous chlorine dioxide fumigation. 62
36126572 2023
43
Newly isolated halotolerant Aspergillus sp. showed high diesel degradation efficiency under high salinity environment aided with hematite. 62
36444053 2023
44
Imaging of Uncommon Bacterial, Rickettsia, Spirochete, and Fungal Infections. 62
36404049 2023
45
Aspergillosis ball graft as complication of Covid-19 infection: Case report. 62
36465160 2023
46
Effects of thymol concentration on postharvest diseases and quality of blueberry fruit. 62
36155290 2023
47
The Penicillium digitatum antifungal protein PdAfpB shows high activity against mycobiota involved in sliced bread spoilage. 62
36309457 2023
48
Antibacterial, antifungal, antidiabetic, and antioxidant activities potential of Coleus aromaticus synthesized titanium dioxide nanoparticles. 62
36334834 2023
49
N-acetylation of toxic aromatic amines by fungi: Strain screening, cytotoxicity and genotoxicity evaluation, and application in bioremediation of 3,4-dichloroaniline. 62
36115092 2023
50
Comparison of risk factors and outcome of patients with and without COVID-19-associated pulmonary aspergillosis from Pakistan: A case-control study. 62
36111367 2023

Variations for Aspergillosis

ClinVar genetic disease variations for Aspergillosis:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CLEC1A NM_016511.4(CLEC1A):c.77G>C (p.Gly26Ala) SNV Risk Factor
590287 rs2306894 GRCh37: 12:10251445-10251445
GRCh38: 12:10098846-10098846
2 CLEC7A NM_197947.3(CLEC7A):c.714T>G (p.Tyr238Ter) SNV Risk Factor
4466 rs16910526 GRCh37: 12:10271087-10271087
GRCh38: 12:10118488-10118488

Expression for Aspergillosis

Search GEO for disease gene expression data for Aspergillosis.

Pathways for Aspergillosis

Pathways related to Aspergillosis according to GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 TNF IL6 IL5 IL4 IL1B IL10
2
Show member pathways
13.79 CCL3 CCR6 CLEC7A CSF1 CSF3 ELANE
3
Show member pathways
13.72 TNF TLR4 IL6 IL5 IL4 IL1B
4
Show member pathways
13.59 TNF IL6 IL5 IL4 IL1B IL10
5
Show member pathways
13.54 TNF TLR9 TLR4 TLR2 IL6 IL4
6
Show member pathways
13.5 CCL3 CCR6 CSF1 CSF3 IL10 IL1B
7
Show member pathways
13.44 TNF IL6 IL5 IL4 IL1B IL10
8
Show member pathways
13.42 CCL3 CCR6 CSF1 CSF3 IL10 IL1B
9
Show member pathways
13.02 TLR4 TLR2 IL6 IL4 CSF3 CSF1
10
Show member pathways
12.97 TNF TLR9 TLR4 TLR2 SFTPD MBL2
11
Show member pathways
12.81 TNF TLR9 TLR4 TLR2 IL6 IL1B
12 12.76 CSF1 CSF3 IL10 IL1B IL6
13
Show member pathways
12.74 TNF IL6 IL5 IL4 IL1B IL10
14
Show member pathways
12.73 TNF TLR9 TLR2 IL6 IL1B CLEC7A
15 12.72 TNF TLR9 TLR2 IL4 IL1B IL10
16
Show member pathways
12.69 TNF TLR9 TLR4 TLR2 IL1B
17
Show member pathways
12.69 TLR2 PTX3 MBL2 IFNG ELANE
18
Show member pathways
12.66 TNF IL6 IL1B IL10 IFNG
19
Show member pathways
12.65 TNF TLR9 TLR4 TLR2 IL6 IL1B
20
Show member pathways
12.53 IFNG IL1B IL4 IL6 SFTPD TLR2
21
Show member pathways
12.41 TNF TLR4 IL6 IL1B IFNG
22
Show member pathways
12.34 TNF TLR2 IL6 CSF3
23 12.34 TNF TLR9 TLR4 TLR2 IL6 IFNG
24
Show member pathways
12.31 TLR9 TLR4 TLR2 SFTPD
25
Show member pathways
12.27 TNF IL5 IL4 IL10 IFNG
26 12.25 TNF IL6 IL4 IL1B IL10 IFNG
27 12.24 TNF IL6 IL1B IL10
28
Show member pathways
12.16 TLR9 TLR4 TLR2 CLEC7A
29
Show member pathways
12.16 TLR9 TLR4 TLR2 IL5 IL1B
30 12.15 TNF TLR4 IL6 IL4 IL1B IFNG
31 12.1 TNF IL6 IL4 IL1B IL10
32 12.1 TNF IL6 IL5 IL4 IL10 IFNG
33
Show member pathways
12.07 IL4 IL1B IFNG CCL3
34 12.04 IL6 IL1B IFNG CCL3
35 12.04 TNF IL5 IL4 IL1B IL10 IFNG
36
Show member pathways
12.03 TLR9 TLR4 TLR2 IL6 IL4 IL1B
37
Show member pathways
12.01 TNF TLR9 TLR4 TLR2 IL6 IL1B
38 12 IL6 IL10 CCR6 CCL3
39 11.91 TNF TLR9 IL6 IL1B IL10 IFNG
40 11.9 IL6 IL5 IL4 IFNG
41 11.9 TNF TLR4 IL6 IL4 IL10 IFNG
42 11.88 TNF TLR4 IL6 IL1B
43 11.88 TLR4 IL6 IL10 IFNG
44 11.88 IL6 IL5 IL4 IL10 IFNG
45
Show member pathways
11.84 TNF IL1B IFNG
46 11.84 IL6 IL4 IL1B IFNG
47
Show member pathways
11.83 IFNG IL4 IL5 TNF
48 11.83 TNF TLR4 IL6 IL10 ELANE CCL3
49 11.83 TNF IL5 IL4 IL1B IL10 IFNG
50 11.82 IL10 IL1B IL6 TLR4 TNF

GO Terms for Aspergillosis

Cellular components related to Aspergillosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.13 CCL3 CSF1 CSF3 ELANE IFNG IL10
2 cell surface GO:0009986 10 TNF TLR4 TLR2 MBL2 ELANE CLEC7A
3 extracellular space GO:0005615 9.77 CCL3 CSF1 CSF3 ELANE IFNG IL10

Biological processes related to Aspergillosis according to GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.7 CSF3 IL10 IL1B IL4 IL6 TLR2
2 innate immune response GO:0045087 10.57 TLR9 TLR4 TLR2 SFTPD PTX3 MBL2
3 positive regulation of cell population proliferation GO:0008284 10.54 CLEC7A CSF1 CSF3 IFNG IL1B IL4
4 signal transduction GO:0007165 10.48 CCL3 CCR6 CLEC1A CSF1 CSF3 IFNG
5 positive regulation of cell migration GO:0030335 10.46 CCL3 CLEC7A CSF1 IL1B IL4
6 positive regulation of gene expression GO:0010628 10.45 CCL3 CLEC7A CSF1 IFNG IL1B IL4
7 defense response to bacterium GO:0042742 10.44 ELANE IL10 MBL2 SFTPD TLR4 TLR9
8 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.43 TNF TLR9 TLR4 IL1B CLEC7A
9 cellular response to lipopolysaccharide GO:0071222 10.4 TNF TLR9 TLR4 IL6 IL1B IL10
10 inflammatory response GO:0006954 10.39 CCL3 CLEC7A CSF1 IL1B IL5 IL6
11 defense response to Gram-positive bacterium GO:0050830 10.38 TNF TLR2 MBL2 IL6 IL1B
12 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.38 TNF TLR9 TLR4 TLR2 IL6 IL1B
13 positive regulation of DNA-binding transcription factor activity GO:0051091 10.37 TNF IL6 IL5 IL1B IL10 CSF3
14 positive regulation of inflammatory response GO:0050729 10.36 CCL3 IFNG IL1B TLR2 TLR4 TLR9
15 positive regulation of JNK cascade GO:0046330 10.35 TNF TLR9 TLR4 IL1B
16 cellular response to type II interferon GO:0071346 10.34 TNF TLR4 TLR2 CCL3
17 positive regulation of type II interferon production GO:0032729 10.34 TNF TLR9 TLR4 IL1B CLEC7A
18 positive regulation of tumor necrosis factor production GO:0032760 10.34 TLR9 TLR4 TLR2 IL6 IFNG CLEC7A
19 positive regulation of MAP kinase activity GO:0043406 10.33 ELANE IL1B TLR4 TNF
20 positive regulation of NIK/NF-kappaB signaling GO:1901224 10.33 TNF TLR9 TLR4 TLR2 IL1B
21 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 10.32 IFNG IL4 IL6 TNF
22 negative regulation of interleukin-6 production GO:0032715 10.31 IL10 TLR4 TLR9 TNF
23 humoral immune response GO:0006959 10.31 TNF IL6 IFNG CCR6
24 positive regulation of interleukin-1 beta production GO:0032731 10.31 CCL3 CLEC7A IFNG IL6 TLR4 TNF
25 positive regulation of smooth muscle cell proliferation GO:0048661 10.3 TNF TLR4 IL6 ELANE
26 response to lipopolysaccharide GO:0032496 10.3 CSF1 ELANE IL10 IL1B TLR2 TLR4
27 positive regulation of interleukin-12 production GO:0032735 10.29 CLEC7A IFNG TLR2 TLR4 TLR9
28 regulation of insulin secretion GO:0050796 10.28 TNF IL6 IL1B IFNG
29 positive regulation of B cell proliferation GO:0030890 10.28 IL4 IL5 TLR4 TLR9
30 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.27 TNF IL6 IL5 IL10
31 lipopolysaccharide-mediated signaling pathway GO:0031663 10.27 CCL3 IL1B TLR2 TLR4 TNF
32 immune system process GO:0002376 10.26 TLR9 TLR4 TLR2 SFTPD MBL2 CSF1
33 I-kappaB kinase/NF-kappaB signaling GO:0007249 10.26 IL1B TLR4 TLR9 TNF
34 positive regulation of immunoglobulin production GO:0002639 10.25 IL10 IL5 IL6 TLR9
35 microglial cell activation GO:0001774 10.25 TNF TLR9 TLR2 IL4 IFNG
36 positive regulation of interferon-beta production GO:0032728 10.24 TLR9 TLR4 TLR2
37 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.24 TNF TLR4 IL6 CLEC7A
38 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 10.23 TNF IL1B CLEC7A
39 liver regeneration GO:0097421 10.23 TNF IL6 IL10
40 positive regulation of cytokine production GO:0001819 10.23 IFNG IL10 IL1B TLR9 TNF
41 positive regulation of nitric oxide biosynthetic process GO:0045429 10.23 CLEC7A IFNG IL1B PTX3 TLR4 TNF
42 negative regulation of osteoclast differentiation GO:0045671 10.22 TLR4 IL4 CCL3
43 negative regulation of interleukin-8 production GO:0032717 10.22 TLR9 IL10 ELANE
44 negative regulation of neurogenesis GO:0050768 10.22 IL1B IL6 TNF
45 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 10.22 TLR9 TLR4 TLR2 IFNG
46 positive regulation of interleukin-6 production GO:0032755 10.22 CLEC7A IFNG IL1B IL6 TLR2 TLR4
47 toll-like receptor signaling pathway GO:0002224 10.21 TLR9 TLR4 TLR2
48 positive regulation of osteoclast differentiation GO:0045672 10.21 CSF1 IFNG TNF
49 positive regulation of MHC class II biosynthetic process GO:0045348 10.21 TLR4 IL4 IL10 IFNG
50 positive regulation of interleukin-10 production GO:0032733 10.21 TLR9 TLR4 TLR2 IL6 IL4 CLEC7A

Molecular functions related to Aspergillosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.73 CSF1 CSF3 IL10 IL4 IL5 IL6
2 pattern recognition receptor activity GO:0038187 9.63 TLR9 TLR2 CLEC7A
3 lipopolysaccharide immune receptor activity GO:0001875 9.62 TLR4 TLR2
4 cytokine activity GO:0005125 9.6 TNF IL6 IL5 IL4 IL1B IL10
5 (1->3)-beta-D-glucan binding GO:0001872 9.56 PTX3 CLEC7A

Sources for Aspergillosis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....